Sign in with Google
bearish
Celltrion's FDA CRL Issue Summary
349 Views08 Apr 2018 21:43
Celltrion Inc (068270 KS) is still right at the center of attention among Korean stock short sellers despite its KOSPI move.What is more critical...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 7-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- [Japan M&A] Toyota Inds (6201) Proposed Takeover - It Looks Bad, and It's Worse Than It Looks
- US vs EU: Mutually Assured Destruction?
- TIP Customized Taiwan Select High Dividend Index Rebalance: 22 Changes as Expected
- Mayne Disagrees With Cosette On MAC
- NIFTY200 Momentum30 Index Rebalance Preview: 69% One-Way Turnover & US$1.9bn Trade
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Another Negative Sign for Celltrion: Remsima Retail Price Is Falling Too Fast Too Much30 Aug 2018
- Celltrion (068270): Time Is Not Right for Short Sellers Yet13 Aug 2018
- A Further Study on Celltrion-Celltrion Healthcare Market Cap Spread Movement27 May 2018
- Celltrion's FDA CRL Issue Summary08 Apr 2018
- Celltrion Holdings' ₩200bil CB with Celltrion Healthcare as Pledged Article - Questions to Ask11 Mar 2018
- ION's Celltrion Block Deals - Summary & Impacts06 Mar 2018
- Short Selling Viability Assessment on Celltrion After KOSPI 200 Inclusion02 Mar 2018
x